Medesis Pharma Market Capitalization vs. Current Valuation
ALMDP Stock | EUR 0.35 0.01 2.94% |
For Medesis Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Medesis Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Medesis Pharma SA utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Medesis Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Medesis Pharma SA over time as well as its relative position and ranking within its peers.
Medesis |
Medesis Pharma SA Current Valuation vs. Market Capitalization Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Medesis Pharma's current stock value. Our valuation model uses many indicators to compare Medesis Pharma value to that of its competitors to determine the firm's financial worth. Medesis Pharma SA is number one stock in market capitalization category among its peers. It also is the top company in current valuation category among its peers reporting about 0.65 of Current Valuation per Market Capitalization. The ratio of Market Capitalization to Current Valuation for Medesis Pharma SA is roughly 1.55 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Medesis Pharma's earnings, one of the primary drivers of an investment's value.Medesis Market Capitalization vs. Competition
Medesis Pharma SA is number one stock in market capitalization category among its peers. Market capitalization of Biotechnology industry is presently estimated at about 755.28 Million. Medesis Pharma claims roughly 13.43 Million in market capitalization contributing just under 2% to stocks in Biotechnology industry.
Medesis Current Valuation vs. Market Capitalization
Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Medesis Pharma |
| = | 13.43 M |
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Medesis Pharma |
| = | 8.67 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Medesis Current Valuation vs Competition
Medesis Pharma SA is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Biotechnology industry is presently estimated at about 591.26 Million. Medesis Pharma claims roughly 8.67 Million in current valuation contributing just under 2% to stocks in Biotechnology industry.
Medesis Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Medesis Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Medesis Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Medesis Pharma's change in net profit over the period of time. It can combine multiple indicators of Medesis Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Medesis Pharma SA, a clinical development stage biopharmaceutical company, engages in the development of orally administered molecule drug candidates to address unmet medical needs. The company was founded in 2003 and is based in Montpellier, France. MEDESIS PHARMA is traded on Paris Stock Exchange in France.
Medesis Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Medesis Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Medesis Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Medesis Pharma's important profitability drivers and their relationship over time.
Use Medesis Pharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medesis Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medesis Pharma will appreciate offsetting losses from the drop in the long position's value.Medesis Pharma Pair Trading
Medesis Pharma SA Pair Trading Analysis
The ability to find closely correlated positions to Medesis Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medesis Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medesis Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medesis Pharma SA to buy it.
The correlation of Medesis Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medesis Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medesis Pharma SA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medesis Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Medesis Pharma position
In addition to having Medesis Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Driverless Cars Thematic Idea Now
Driverless Cars
It encompasses large technology companies, automotive makers, security firms, and thematic ETFs across multiple industries. These entities are directly or indirectly involved in shaping the development and marketing of self-driving vehicles. The Driverless Cars theme has 36 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Driverless Cars Theme or any other thematic opportunities.
View All Next | Launch |
Additional Tools for Medesis Stock Analysis
When running Medesis Pharma's price analysis, check to measure Medesis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medesis Pharma is operating at the current time. Most of Medesis Pharma's value examination focuses on studying past and present price action to predict the probability of Medesis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medesis Pharma's price. Additionally, you may evaluate how the addition of Medesis Pharma to your portfolios can decrease your overall portfolio volatility.